• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

醛固酮与一生的心血管风险

Aldosterone and Cardiovascular Risk Across the Lifespan.

作者信息

Ananda Roshan A, Mori Trevor A, Yang Jun

机构信息

Department of General Medicine, Box Hill Hospital, Melbourne, VIC 3128, Australia.

Medical School, Royal Perth Hospital Unit, University of Western Australia, Perth, WA 6000, Australia.

出版信息

Metabolites. 2025 Aug 17;15(8):553. doi: 10.3390/metabo15080553.

DOI:10.3390/metabo15080553
PMID:40863169
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12388298/
Abstract

Aldosterone excess, particularly in the context of primary aldosteronism, is associated with adverse cardiovascular outcomes. Historically considered a condition of resistant hypertension with hypokalaemia, patients with primary aldosteronism often experienced prolonged diagnostic delay with significant end-organ damage involving the renal, cardiovascular, and central nervous systems at diagnosis. Emerging research has revealed a wide spectrum of renin-independent aldosteronism, ranging from subclinical disease with normal or mildly elevated BP to overt disease marked by resistant hypertension and cardiovascular complications. Subclinical forms of primary aldosteronism have been identified across all age groups, and it is increasingly linked to early signs of adverse cardiac remodelling, even in young adults. Notably, adverse cardiac remodelling was independent of blood pressure. Furthermore, primary aldosteronism confers excess cardiovascular morbidity and mortality compared to blood-pressure-matched essential hypertension. Importantly, these risks can be mitigated through timely diagnosis and treatment with mineralocorticoid receptor antagonists. In this narrative review, we explore the cardiovascular consequences of aldosterone excess, discuss the pathophysiological mechanisms underlying cardiac remodelling, and examine the implications of renin-independent aldosteronism for cardiovascular risk across the lifespan.

摘要

醛固酮过多,尤其是在原发性醛固酮增多症的情况下,与不良心血管结局相关。原发性醛固酮增多症患者历史上被认为是伴有低钾血症的难治性高血压,往往诊断延迟时间长,诊断时肾脏、心血管和中枢神经系统等重要终末器官受到显著损害。新出现的研究揭示了一系列不依赖肾素的醛固酮增多症,从血压正常或轻度升高的亚临床疾病到以难治性高血压和心血管并发症为特征的显性疾病。原发性醛固酮增多症的亚临床形式在所有年龄组中均有发现,甚至在年轻人中也越来越多地与不良心脏重塑的早期迹象相关。值得注意的是,不良心脏重塑与血压无关。此外,与血压匹配的原发性高血压相比,原发性醛固酮增多症会导致更多的心血管发病率和死亡率。重要的是,通过及时诊断并用盐皮质激素受体拮抗剂治疗,这些风险可以得到缓解。在这篇叙述性综述中,我们探讨醛固酮过多对心血管的影响,讨论心脏重塑的病理生理机制,并研究不依赖肾素的醛固酮增多症对全生命周期心血管风险的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9b2/12388298/698a44c07374/metabolites-15-00553-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9b2/12388298/cb53b5160ea0/metabolites-15-00553-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9b2/12388298/698a44c07374/metabolites-15-00553-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9b2/12388298/cb53b5160ea0/metabolites-15-00553-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9b2/12388298/698a44c07374/metabolites-15-00553-g002.jpg

相似文献

1
Aldosterone and Cardiovascular Risk Across the Lifespan.醛固酮与一生的心血管风险
Metabolites. 2025 Aug 17;15(8):553. doi: 10.3390/metabo15080553.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline.原发性醛固酮增多症:内分泌学会临床实践指南
J Clin Endocrinol Metab. 2025 Aug 7;110(9):2453-2495. doi: 10.1210/clinem/dgaf284.
4
Subclinical Primary Aldosteronism and Major Adverse Cardiovascular Events: A Longitudinal Population-Based Cohort Study.亚临床原发性醛固酮增多症与主要不良心血管事件:一项基于人群的纵向队列研究。
Circulation. 2025 Jul 9. doi: 10.1161/CIRCULATIONAHA.124.073507.
5
Primary Aldosteronism and Cognitive Dysfunction: A Case-Control Study.原发性醛固酮增多症与认知功能障碍:一项病例对照研究。
J Clin Med. 2025 Jun 30;14(13):4618. doi: 10.3390/jcm14134618.
6
Higher blood pressure targets for hypertension in older adults.老年人高血压的更高血压目标
Cochrane Database Syst Rev. 2024 Dec 17;12(12):CD011575. doi: 10.1002/14651858.CD011575.pub3.
7
Replacing salt with low-sodium salt substitutes (LSSS) for cardiovascular health in adults, children and pregnant women.用低钠盐替代物(LSSS)代替盐以促进成年人、儿童和孕妇的心血管健康。
Cochrane Database Syst Rev. 2022 Aug 10;8(8):CD015207. doi: 10.1002/14651858.CD015207.
8
Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis.原发性醛固酮增多症与原发性高血压的心血管事件和靶器官损害的比较:系统评价和荟萃分析。
Lancet Diabetes Endocrinol. 2018 Jan;6(1):41-50. doi: 10.1016/S2213-8587(17)30319-4. Epub 2017 Nov 9.
9
Blood pressure targets for hypertension in people with chronic renal disease.高血压合并慢性肾脏病患者的血压目标。
Cochrane Database Syst Rev. 2024 Oct 15;10(10):CD008564. doi: 10.1002/14651858.CD008564.pub3.
10
Systemic Inflammatory Response Syndrome全身炎症反应综合征

本文引用的文献

1
Phase 2a Study of Baxdrostat in Primary Aldosteronism.巴多司他用于原发性醛固酮增多症的2a期研究。
N Engl J Med. 2025 Jul 31;393(5):515-518. doi: 10.1056/NEJMc2508629. Epub 2025 Jul 13.
2
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline.原发性醛固酮增多症:内分泌学会临床实践指南
J Clin Endocrinol Metab. 2025 Aug 7;110(9):2453-2495. doi: 10.1210/clinem/dgaf284.
3
Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension.洛伦德司他对血压控制不佳患者的疗效与安全性
N Engl J Med. 2025 May 8;392(18):1813-1823. doi: 10.1056/NEJMoa2501440. Epub 2025 Apr 23.
4
Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism: A Pilot Randomized Controlled Trial.非奈利酮治疗原发性醛固酮增多症患者的疗效和安全性:一项前瞻性随机对照试验。
Circulation. 2025 Jan 14;151(2):196-198. doi: 10.1161/CIRCULATIONAHA.124.071452. Epub 2025 Jan 13.
5
Relationship Between Renin, Aldosterone, Aldosterone-to-Renin Ratio and Arterial Stiffness and Left Ventricular Mass Index in Young Adults.年轻成年人中肾素、醛固酮、醛固酮与肾素比值与动脉僵硬度及左心室质量指数的关系
Circulation. 2024 Dec 17;150(25):2019-2030. doi: 10.1161/CIRCULATIONAHA.124.070039. Epub 2024 Oct 1.
6
Interleukin 6 plasma levels are associated with progression of coronary plaques.白细胞介素 6 血浆水平与冠状动脉斑块进展有关。
Open Heart. 2024 Sep 19;11(2):e002773. doi: 10.1136/openhrt-2024-002773.
7
Prevalence and Risk Factors for Secondary Hypertension in Young Adults.年轻人继发性高血压的患病率及危险因素。
Hypertension. 2024 Nov;81(11):2340-2349. doi: 10.1161/HYPERTENSIONAHA.124.22753. Epub 2024 Sep 19.
8
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.非奈利酮治疗射血分数轻度降低或保留的心力衰竭。
N Engl J Med. 2024 Oct 24;391(16):1475-1485. doi: 10.1056/NEJMoa2407107. Epub 2024 Sep 1.
9
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.非奈利酮用于伴2型糖尿病的心力衰竭和慢性肾脏病:FINE-HEART心血管、肾脏及死亡率结局的汇总分析
Nat Med. 2024 Dec;30(12):3758-3764. doi: 10.1038/s41591-024-03264-4. Epub 2024 Sep 1.
10
Aldosterone is Associated With New-onset Cerebrovascular Events in Patients With Hypertension and White Matter Lesions: A Cohort Study.醛固酮与高血压伴脑白质病变患者新发脑血管事件的相关性:一项队列研究。
Endocr Pract. 2024 Aug;30(8):718-725. doi: 10.1016/j.eprac.2024.05.004. Epub 2024 May 9.